Page 19 - TD-2-3

Tumor Discovery Targeted drug delivery systems for the treatment of tumors

by tumor cells. Therefore, these lipid nanocarriers show challenge, docetaxel-loaded SLNs (SLN-DTX) were
promise for both therapeutic applications and tumor prepared using Compritol 888 ATO. These SLN-DTX
monitoring through modified uptake of low-density nanoparticles exhibited remarkable stability with a
lipoproteins. nanodimensional size of 128 nm, resulting in enhanced
Bhagwat et al. developed transferrin-decorated entrapment efficiency (86%) and controlled in vitro
SLNs containing tamoxifen citrate for improved breast release of docetaxel. Notably, the developed SLN-DTX
tumor targeting with minimal toxicity . Tamoxifen demonstrated significantly greater cellular uptake and
[98]
citrate, a selective estrogen receptor modulator, blocks accumulation in the G2–M phase (73%) when compared
the passage of estrogen to breast tissues, inhibiting to the free drug (23%), ultimately leading to the induction
tumor cell growth. However, the associated uterine of apoptosis in tumor cells. Histological investigations
toxicity associated with tamoxifen limits its broader confirmed the antitumor activity of SLN-DTX and its
application in solid tumor management. The developed potential for spontaneously preventing metastasis in
transferrin-modified tamoxifen citrate-conjugated SLNs a murine mammary cancer model (4T1) [99,100] . Table 6
exhibited preferential accumulation at the target site summarizes a comprehensive overview of various SLNs
(in MCF-7 cells), were qualitatively taken up at the M2 and their chemopreventive potential.
level of the cell cycle, and significantly alleviated human
breast cancer in a concentration-dependent manner. The (b) Nanostructured lipid carriers
solubility and bioavailability of the poorly water-soluble Biocompatible NLCs are second-generation lipid-
candidate efavirenz can be modified through the use of based drug carriers that effectively shield drugs from
SLNs. Efavirenz, a non-nucleoside reverse transcriptase degradation, extending their stability and bioavailability.
inhibitor, is widely used to treat HIV-positive patients and NLCs offer compelling advantages over traditional
for antineoplastic management. lipid carriers, including increased storage permanency,
Metastasis represents a critical stage in the progression improved solubility, enhanced permeability, and minimal
of malignant tumors, such as breast cancer, and is adverse effects on associated cells. These formulations are
associated with high mortality rates. To address this biocompatible and hold great promise for targeted cancer

Table 6. Developed solid lipid nanoparticles and their associated antitumor usages
Drug candidate Purpose Research highlights Application References
5-fluorouracil (5-FU) Develop a biocompatible and Developed 5-FU/SLNs that exhibited a 3.6-fold area Colorectal cancer [101]
therapeutically effective 5-FU/ under the curve, demonstrating superior inhibition
SLNs. of tumor cells compared to bare 5-FU. In addition,
the extent of HER2 receptors and HCT116 cells was
markedly reduced in liver and kidney tissues
Alpha(v)beta(3) Preparation of novel receptor Developed RGD-SLNs exhibited active tumor Chemotherapy [102]
integrin cyclic targeting (overexpressive alpha(v) targeting on intravenous administration in mice and
arginyl-glycyl- beta(3) integrin receptors) and bearing xenograft human breast tumor. The system chemoimaging
aspartic acid (RGD) near-infrared light-emitting SLNs was specifically distributed in the liver, spleen, and
for enhanced biodistribution and tumor blood vessels
accumulation.
Camptothecin (CPT) Development of pH-sensitive CPT-embedded PEGylated SLNs were spherical, Chemotherapy [103]
SLN system for prolonged small (53 nm), and exhibited excellent entrapment
accumulation in different tumor efficiency (99%). The in vitro drug release profile
sites. displayed a pH-dependent pattern of drug release.
Developed CPT–PEG–SLNs were effective against
diverse carcinoma, including lungs (CRL5802,
NCL-H358, and CL1-5), colon (HCT-116), and liver
(HCC36).
Resveratrol Inhibition of breast tumor The developed system was spherical, negatively Breast cancer [104]
proliferation through resveratrol- charged, and smaller compared to bare resveratrol. treatment
SLNs Western blot analysis suggested superior inhibition
efficiency against the proliferation of MDA-MB-231
cells and minimized expression of cyclin D1/c-Myc
that explored potential usage for the management of
breast tumors

Volume 2 Issue 3 (2023) 13 https://doi.org/10.36922/td.1356